Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients
Abstract Chronic myeloid leukemia (CML) is a form of myeloproliferative neoplasm caused by the oncogenic tyrosine kinase BCR-ABL. Although tyrosine kinase inhibitors have dramatically improved the prognosis of patients with CML, several problems such as resistance and recurrence still exist. Immunol...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ca1582ae26944192807940863f8aa2cc |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ca1582ae26944192807940863f8aa2cc |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ca1582ae26944192807940863f8aa2cc2021-12-02T17:41:18ZCompromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients10.1038/s41598-021-97371-82045-2322https://doaj.org/article/ca1582ae26944192807940863f8aa2cc2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97371-8https://doaj.org/toc/2045-2322Abstract Chronic myeloid leukemia (CML) is a form of myeloproliferative neoplasm caused by the oncogenic tyrosine kinase BCR-ABL. Although tyrosine kinase inhibitors have dramatically improved the prognosis of patients with CML, several problems such as resistance and recurrence still exist. Immunological control may contribute to solving these problems, and it is important to understand why CML patients fail to spontaneously develop anti-tumor immunity. Here, we show that differentiation of conventional dendritic cells (cDCs), which are vital for anti-tumor immunity, is restricted from an early stage of hematopoiesis in CML. In addition, we found that monocytes and basophils, which are increased in CML patients, express high levels of PD-L1, an immune checkpoint molecule that inhibits T cell responses. Moreover, RNA-sequencing analysis revealed that basophils express genes related to poor prognosis in CML. Our data suggest that BCR-ABL not only disrupts the “accelerator” (i.e., cDCs) but also applies the “brake” (i.e., monocytes and basophils) of anti-tumor immunity, compromising the defense against CML cells.Ibuki HaradaHaruka SasakiKoichi MurakamiAkira NishiyamaJun NakabayashiMotohide IchinoTakuya MiyazakiKen KumagaiKenji MatsumotoMaki HagiharaWataru KawaseTakayoshi TachibanaMasatsugu TanakaTomoyuki SaitoHeiwa KanamoriHiroyuki FujitaShin FujisawaHideaki NakajimaTomohiko TamuraNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Ibuki Harada Haruka Sasaki Koichi Murakami Akira Nishiyama Jun Nakabayashi Motohide Ichino Takuya Miyazaki Ken Kumagai Kenji Matsumoto Maki Hagihara Wataru Kawase Takayoshi Tachibana Masatsugu Tanaka Tomoyuki Saito Heiwa Kanamori Hiroyuki Fujita Shin Fujisawa Hideaki Nakajima Tomohiko Tamura Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients |
| description |
Abstract Chronic myeloid leukemia (CML) is a form of myeloproliferative neoplasm caused by the oncogenic tyrosine kinase BCR-ABL. Although tyrosine kinase inhibitors have dramatically improved the prognosis of patients with CML, several problems such as resistance and recurrence still exist. Immunological control may contribute to solving these problems, and it is important to understand why CML patients fail to spontaneously develop anti-tumor immunity. Here, we show that differentiation of conventional dendritic cells (cDCs), which are vital for anti-tumor immunity, is restricted from an early stage of hematopoiesis in CML. In addition, we found that monocytes and basophils, which are increased in CML patients, express high levels of PD-L1, an immune checkpoint molecule that inhibits T cell responses. Moreover, RNA-sequencing analysis revealed that basophils express genes related to poor prognosis in CML. Our data suggest that BCR-ABL not only disrupts the “accelerator” (i.e., cDCs) but also applies the “brake” (i.e., monocytes and basophils) of anti-tumor immunity, compromising the defense against CML cells. |
| format |
article |
| author |
Ibuki Harada Haruka Sasaki Koichi Murakami Akira Nishiyama Jun Nakabayashi Motohide Ichino Takuya Miyazaki Ken Kumagai Kenji Matsumoto Maki Hagihara Wataru Kawase Takayoshi Tachibana Masatsugu Tanaka Tomoyuki Saito Heiwa Kanamori Hiroyuki Fujita Shin Fujisawa Hideaki Nakajima Tomohiko Tamura |
| author_facet |
Ibuki Harada Haruka Sasaki Koichi Murakami Akira Nishiyama Jun Nakabayashi Motohide Ichino Takuya Miyazaki Ken Kumagai Kenji Matsumoto Maki Hagihara Wataru Kawase Takayoshi Tachibana Masatsugu Tanaka Tomoyuki Saito Heiwa Kanamori Hiroyuki Fujita Shin Fujisawa Hideaki Nakajima Tomohiko Tamura |
| author_sort |
Ibuki Harada |
| title |
Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients |
| title_short |
Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients |
| title_full |
Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients |
| title_fullStr |
Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients |
| title_full_unstemmed |
Compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients |
| title_sort |
compromised anti-tumor–immune features of myeloid cell components in chronic myeloid leukemia patients |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/ca1582ae26944192807940863f8aa2cc |
| work_keys_str_mv |
AT ibukiharada compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT harukasasaki compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT koichimurakami compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT akiranishiyama compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT junnakabayashi compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT motohideichino compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT takuyamiyazaki compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT kenkumagai compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT kenjimatsumoto compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT makihagihara compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT watarukawase compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT takayoshitachibana compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT masatsugutanaka compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT tomoyukisaito compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT heiwakanamori compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT hiroyukifujita compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT shinfujisawa compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT hideakinakajima compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients AT tomohikotamura compromisedantitumorimmunefeaturesofmyeloidcellcomponentsinchronicmyeloidleukemiapatients |
| _version_ |
1718379729279516672 |